Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2024 –2030 | |
|
|
|
| USD 216.72 | |
| % | |
|
Middle East and Africa Acute Myeloid Leukemia Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Tests, Biomarker Test, Immunophenotyping, Genetic Tests, and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), Monocytic (M5), Erythroleukemia (M6), and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, and 65 and Above), Gender (Male and Female), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centres, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales) Industry Trends and Forecast to 2030.
Get Exclusive Sample Copy of this Report Here
Due to the rising healthcare expenditure, there is a boost in the market growth, and this may result in better provisions of R&D opportunities. Apart from this, the increasing clinical research and diagnostic laboratories for the diagnosis of cancer are allowing the market to expand.
Get Exclusive Sample Copy of this Report Here
Get Exclusive Sample Copy of this Report Here
The Middle East and Africa acute myeloid leukemia diagnostics market is expected to grow in the forecast period of 2023 to 2030. Data Bridge Market Research analyzes that the market is growing with a CAGR of 9.0% in the forecast period of 2023 to 2030 and is expected to reach USD 216.72 million by 2030.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable to 2020-2016)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Tests, Biomarker Test, Immunophenotyping, Genetic Tests, and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), Monocytic (M5), Erythroleukemia (M6), and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, and 65 and Above), Gender (Male and Female), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centres, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales).
|
|
Countries Covered
|
South Africa, Saudi Arabia, UAE, Egypt, Israel, and rest of Middle East and Africa.
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Abbott, QIAGEN, Agilent Technologies, Inc., Exact Sciences Corporation, Hologic Inc., Illumina, Inc., BD, Quest Diagnostics Incorporated, and Bio-Rad Laboratories, Inc. among others.
|
Market Definition
The most common form of blood cancer, acute myeloid leukemia (AML), is also one of the uncommon forms of leukemia. This form of cancer invades in blood, which then spreads to nearby organs and bodily systems. Specialists must manually diagnose cancer and non-cancer cells by examining cell images under a microscope and providing labels through annotation.
Rising healthcare expenditure can result in better provisions of R&D opportunities, which also propel business growth. The growing plethora of clinical research and diagnostic laboratories for the pre-testing of cancer is allowing the market to expand.
The increasing number of cancer cases and increasing awareness of leukemia have led to increased market growth.
The Middle East and Africa acute myeloid leukemia diagnostics market is growing in the forecast year due to the rise in market players and the availability of advanced imaging instruments and consumables. Along with this, manufacturers are engaged in R&D activity for launching products in the market. The increasing R&D and pre-testing are further boosting the market growth. However, strict regulations and standards for the approval and commercialization of cancer diagnostic products and late diagnosis are expected to act as a challenge to market growth.
This section deals with understanding the market drivers, restraints, opportunities, and challenges. All of this is discussed in detail below:
DRIVERS
All ages can be affected by leukemia. Leukemia can be difficult to diagnose because, despite its wide range of signs and symptoms, it is non-specific and can be linked to other, more widespread medical conditions. AML is one of the four common types of leukemia in adults. It occurs less frequently. It is slightly more common among men than women, however, the average lifetime risk of getting AML in both sexes is about ½ of 1% on average.
AML is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. Although it can be diagnosed at any age, it is uncommon before age 45. The average age of diagnosis is age 68. Rising maternal obesity rates may be partially responsible for the rise in the prevalence of AML.
Due to various risk factors, AML incidence has been rising, becoming a significant socio-economic issue. This is expected to act as a driver for market growth.
The most common form of blood cancer, AML, is also one of the uncommon forms of leukemia. This form of cancer invades in blood, which then spreads to nearby organs and bodily systems. Specialists must manually diagnose cancer and non-cancer cells by examining cell images under a microscope and providing labels through annotation. However, this hand microscopic examination is time-consuming and could give an incorrect diagnosis.
The risk of prescribing incorrect drugs was then reduced using computerized software. The creation of an automatic and reliable classification system became vital to stop the devastating effects of leukemia disease. Multiple segmentation techniques constituted the foundation of the existing leukemia classification algorithms.
The development of several new diagnostic methods will increase the market growth as many new and advanced products are launched. Hence, it is expected to create demand for acute leukemic cancer diagnostic products in the market.
RESTRAINTS
The stringent regulations for the commercialization of any product in the market are proving to be a big challenge for the manufacturers of cancer diagnostic products that have regulations and a different body for the regulatory procedures.
Manufacturers first have to check the CE mark approval for their product's commercialization into the market. The stringent regulatory policies are expected to hinder the growth and development of the market.
Cancer is the leading cause of death in the world. However, if they are identified early on and given the right care, some cancers can be cured. The diagnostic process may experience delays in cancer diagnosis. When patients overlook or fail to respond to potential cancerous signs, the diagnosis gets delayed. The main cause of delayed presentation is the lack of public knowledge of early cancer signs, especially if such symptoms are unusual.
The late diagnosis often results from these factors, which result in poor prognosis. Thus, these are expected to restrain the market growth.
OPPORTUNITY/CHALLENGES
Leukemia is fatal cancer, and the diagnosis process of leukemia also has safety issues. It is not cost-effective. One of the most costly medical disorders to treat is cancer. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and systemic therapy. Health insurance premiums for cancer patients are now more expensive than in the past. In addition, their copayment, deductible, and coinsurance costs are rising.
Henceforth, the current leukemia diagnosis process has safety, cost, and convenience issues, which are expected to act as a challenge to market growth.
Recent Developments
The Middle East and Africa acute myeloid leukemia diagnostics market is segmented into seven notable segments based on product type, test type, cancer type, age group, gender, end user, and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
Based on product type, the market is segmented into instruments and consumables & accessories.
Test Type
Based on test type, the market is segmented into blood test, imaging test, bone marrow test, genetic testing, biomarker test, Immunophenotyping, and others.
Cancer Type
Based on cancer type, the market is segmented into myeloblastic (M0), myeloblastic (M1), myeloblastic (M2), promyelocytic (M3), myelomonocytic (M4), monocytic (M5), erythroleukemia (M6), and megakaryocytic (M7).
Age Group
Based on age group, the market is segmented into below 21, 21-29, 30-65, and 65 and above.
Gender
Based on gender, the market is segmented into male and female.
End User
Based on end user, the market is segmented into hospital, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.
Distribution Channel
Based on distribution channel, the market is segmented into direct tender and retail sales.
The Middle East and Africa acute myeloid leukemia diagnostics market is analyzed and market size insights and trends are provided by country based on product type, test type, cancer type, age group, gender, end user, and distribution channel.
The countries covered in this market report are South Africa, Saudi Arabia, UAE, Egypt, Israel, and rest of Middle East and Africa as referenced above.
South Africa dominates the Middle East and Africa acute myeloid leukemia diagnostics market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the novel technological advancements in leukemia diagnostics in the region, growing R&D investments, and the launch of new products that are boosting market growth.
The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Middle East and Africa brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
The Middle East and Africa acute myeloid leukemia diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the Middle East and Africa acute myeloid leukemia diagnostics market are Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Abbott, QIAGEN, Agilent Technologies, Inc., Exact Sciences Corporation, Hologic Inc., Illumina, Inc., BD, Quest Diagnostics Incorporated, and Bio-Rad Laboratories, Inc. among others.
SKU-
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS
5.1 REGULATORY SCENARIO IN THE U.S.
5.2 REGULATORY SCENARIO IN AUSTRALIA
5.3 REGULATORY SCENARIO IN JAPAN
5.4 REGULATORY SCENARIO IN CHINA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER
6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS
6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER
6.2 RESTRAINTS
6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS
6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA
6.3 OPPORTUNITIES
6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA
6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS
6.4 CHALLENGES
6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 BIOPSY INSTRUMENTS
7.2.1.1 BONE MARROW BIOPSY
7.2.1.2 NEEDLE BIOPSY
7.2.1.3 SURGICAL BIOPSY
7.2.1.4 OTHERS
7.2.2 PATHOLOGY-BASED INSTRUMENTS
7.2.2.1 PCR INSTRUMENTS
7.2.2.2 SLIDE STAINING SYSTEMS
7.2.2.3 TISSUE PROCESSING SYSTEMS
7.2.2.4 CELL PROCESSORS
7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS
7.2.3 IMAGING INSTRUMENTS
7.2.3.1 ULTRASOUND SYSTEMS
7.2.3.2 CT SYSTEMS
7.2.3.3 MRI SYSTEMS
7.2.3.4 OTHERS
7.2.4 OTHERS
7.3 CONSUMABLES & ACCESSORIES
7.3.1 KITS
7.3.1.1 PCR KITS
7.3.1.2 DNA POLYMERASE KITS
7.3.1.3 NUCLEIC ACID ISOLATION KITS
7.3.1.4 OTHERS
7.3.2 REAGENTS
7.3.2.1 ASSAYS
7.3.2.2 BUFFERS
7.3.2.3 PRIMERS
7.3.2.4 OTHERS
7.3.3 PROBES
7.3.4 OTHER CONSUMABLES
8 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 BLOOD TEST
8.2.1 COMPLETE BLOOD COUNT (CBC)
8.2.2 BLOOD CHEMISTRY TESTS
8.2.3 OTHERS
8.3 IMAGING TEST
8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN
8.3.2 MRI
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
8.3.4 OTHERS
8.4 BONE MARROW TESTS
8.4.1 BONE MARROW ASPIRATE
8.4.2 BONE MARROW BIOPSY
8.4.3 OTHERS
8.5 GENETIC TESTS
8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
8.5.2 KARYOTYPING
8.5.3 OTHERS
8.6 BIOMARKER TEST
8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER
8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER
8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER
8.7 IMMUNOPHENOTYPING
8.7.1 FLOW CYTOMETRY
8.7.2 IMMUNOHISTOCHEMISTRY
8.7.3 OTHERS
8.8 OTHERS
9 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE
9.1 OVERVIEW
9.2 MYELOBLASTIC (M0)
9.3 MYELOBLASTIC (M1)
9.4 MYELOBLASTIC (M2)
9.5 PROMYELOCYTIC (M3)
9.6 MYELOMONOCYTIC (M4)
9.7 MONOCYTIC (M5)
9.8 ERYTHROLEUKEMIA (M6)
9.9 MEGAKARYOCYTIC (M7)
10 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 65 AND ABOVE
10.3 30-65
10.4 BELOW 21
10.5 21-29
11 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER
11.1 OVERVIEW
11.2 MALE
11.3 FEMALE
12 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 ASSOCIATED LABS
12.4 INDEPENDENT DIAGNOSTIC LABORATORIES
12.5 DIAGNOSTIC IMAGING CENTERS
12.6 CANCER RESEARCH INSTITUTES
12.7 OTHERS
13 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
14 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION
14.1 MIDDLE EAST AND AFRICA
14.1.1 SOUTH AFRICA
14.1.2 SAUDI ARABIA
14.1.3 UAE
14.1.4 EGYPT
14.1.5 ISRAEL
14.1.6 REST OF MIDDLE EAST AND AFRICA
15 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 CANON MEDICAL SYSTEMS CORPORATION.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 SYSMEX CORPORATION
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 EPIGENOMICS AG.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 MYRIAD GENETICS, INC..
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 F. HOFFMANN- LA ROCHE LTD
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 AGILENT TECHNOLOGIES, INC.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BD
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 BIOMERIEUX
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 BIO-RAD LABORATORIES, INC.
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 DIASORIN S.P.A.
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 EXACT SCIENCES CORPORATION
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 FONAR CORP.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 HOLOGIC INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 ILLUMINA, INC.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 KONINKLIJKE PHILIPS N.V.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 MEDONICA CO. LTD
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 MERCK KGAA
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 PLEXBIO
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENTS
17.21 QIAGEN
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
17.22 QUEST DIAGNOSTICS INCORPORATED
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENTS
17.23 SIEMENS HEALTHCARE GMBH
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 SONIC HEALTHCARE
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENT
17.25 STERNMED GMBH
17.25.1 COMPANY SNAPSHOT
17.25.2 PRODUCT PORTFOLIO
17.25.3 RECENT DEVELOPMENTS
17.26 THERMO FISHER SCIENTIFIC INC.
17.26.1 COMPANY SNAPSHOT
17.26.2 REVENUE ANALYSIS
17.26.3 PRODUCT PORTFOLIO
17.26.4 RECENT DEVELOPMENT
17.27 TIME MEDICAL HOLDING
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA
TABLE 2 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA CONSUMABLES AND ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA MYELOBLASTIC (M0) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA MYELOBLASTIC (M1) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA MYELOBLASTIC (M2) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA PROMYELOCYTIC (M3) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA MYELOMONOCYTIC (M4) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA MONOCYTIC (M5) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA ERYTHROLEUKEMIA (M6) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA MEGAKARYOCYTIC (M7) ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA 65 AND ABOVE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA 30-65 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA BELOW 21 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA 21-29 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA MALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA FEMALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA HOSPITALS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA ASSOCIATED LABS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA DIAGNOSTIC IMAGING CENTERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA CANCER RESEARCH INSTITUTES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA DIRECT TENDER IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA RETAIL SALES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 74 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 SOUTH AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 76 SOUTH AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 SOUTH AFRICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 78 SOUTH AFRICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 SOUTH AFRICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 80 SOUTH AFRICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 81 SOUTH AFRICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 82 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 83 SOUTH AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 SOUTH AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 85 SOUTH AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 86 SOUTH AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 87 SOUTH AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 88 SOUTH AFRICA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 89 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 90 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 91 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 92 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 93 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 94 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 SAUDI ARABIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 96 SAUDI ARABIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 97 SAUDI ARABIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 98 SAUDI ARABIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 SAUDI ARABIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 100 SAUDI ARABIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 101 SAUDI ARABIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 102 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 103 SAUDI ARABIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 104 SAUDI ARABIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 SAUDI ARABIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 106 SAUDI ARABIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 107 SAUDI ARABIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 108 SAUDI ARABIA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 109 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 110 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 111 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 112 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 113 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 114 UAE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 115 UAE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 116 UAE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 117 UAE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 118 UAE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 119 UAE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 120 UAE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 121 UAE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 UAE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 123 UAE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 124 UAE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 125 UAE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 126 UAE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 127 UAE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 128 UAE GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 129 UAE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 130 UAE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 131 UAE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 132 UAE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 133 UAE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 134 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 135 EGYPT INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 136 EGYPT PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 137 EGYPT IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 138 EGYPT BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 EGYPT CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 140 EGYPT KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 141 EGYPT REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 142 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 143 EGYPT IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 144 EGYPT BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 145 EGYPT BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 146 EGYPT BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 147 EGYPT IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 148 EGYPT GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 149 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 150 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 151 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 152 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 153 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 154 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 155 ISRAEL INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 156 ISRAEL PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 157 ISRAEL IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 158 ISRAEL BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 159 ISRAEL CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 160 ISRAEL KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 161 ISRAEL REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 162 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 163 ISRAEL IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 164 ISRAEL BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 165 ISRAEL BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 166 ISRAEL BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 167 ISRAEL IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 168 ISRAEL GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 169 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 170 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 171 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 172 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 173 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 174 REST OF MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
FIGURE 1 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : MARKET END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : SEGMENTATION
FIGURE 11 THE GROWING PREVALENCE OF LEUKEMIA CANCER IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN THE FORECAST PERIOD
FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET
FIGURE 14 NUMBER OF PREVALENCE OF LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES)
FIGURE 15 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES)
FIGURE 16 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 17 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 18 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 19 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 21 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 22 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 23 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 24 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 25 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 26 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 27 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 28 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 29 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 30 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 31 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 32 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2022
FIGURE 33 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)
FIGURE 34 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 35 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 36 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 37 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 38 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 39 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 41 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 42 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 43 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 45 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 46 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 47 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 48 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)
FIGURE 49 MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.